Biomedical Advanced Research and Development Authority Archives

U.S. purchases more monkeypox vaccine doses from Bavarian Nordic

Bavarian Nordic A/S (OMX:BAVA) has announced that the U.S. Biomedical Advanced Research and Development Authority (BARDA) has ordered an additional 2.5 million doses of liquid-frozen Jynneos vaccine.

FDA first approved Jynneos, a non-replicating smallpox and monkeypox vaccine, in 2019.

It continues to be the only FDA-approved vaccine indicated for monkeypox.

The company will begin deliveries in the recent contract in the fourth quarter of 2022 and continue into early 2023.

In May, Bavarian Nordic announced that it had secured a separate BARDA contract worth $119 million to convert bulk vaccine into freeze-dried doses of Jynneos vaccine.

In all, the company will supply a total of 4.4 million doses to the U.S. in 2022 and 2023.

The company’s share price increased 3.89% to 243.00 Danish Krone.

Earlier this week, the U.S. Department of Health and Human Services (HHS) announced an updated nationwide monkeypox vaccination strategy t…

Paratek Pharmaceuticals wins more funding from BARDA

Antibiotic specialist Paratek Pharmaceuticals (NSDQ: PRTK) has secured additional funding from the Biomedical Advanced Research and Development Authority (BARDA) to develop the antibiotic Nuzyra (omadacycline) for anthrax.

Specifically, the latest funding will support Paratek’s program to develop the tetracycline-class antibiotic Nuzyra as a post-exposure prophylaxis and pulmonary anthrax treatment.

The latest BARDA funding will support studies valued at approximately $19 million. Overall, the BARDA contract now has a total value of $340 million.

Last week, Paratek released data related to Nuzyra for treating pneumonia and skin infections.

“Paratek has been studying Nuzyra against select biothreat pathogens for over a decade, and we are excited to build on the promising in vitro and in vivo animal data and advance the pulmonary anthrax development program for treatment and PEP,” said Randy Brenner, chief development and regulatory officer of Parat…

Selux Diagnostics receives BARDA funding to speed development of rapid AST platform

[Image courtesy of Selux Diagnostics]

The Biomedical Advanced Research and Development Authority (BARDA) has awarded Selux Diagnostics $9.6 million to fund its development of a next-generation phenotyping (NGP) platform to treat superbug infections and combat antibiotic resistance.

The $9.6 million is the third funding tranche the company has received from BARDA as part of the company’s milestone-based contract. BARDA has provided Selux $30.4 million in funding to date.

“BARDA has offered strong support in the development of the Selux NGP platform and has led the way in the successful government-private sector collaboration to solve one of the world’s toughest health challenges — antibiotic resistance,” said Selux CEO Steve Lufkin. “This leadership is especially vital now, as new data indicate the antibiotic resistance crisis is even more threatening than previously understood. BARDA is leveraged…